Diabetes drugs 'block cancers'

Metformin and glitazones may reduce cancer risk in people with type-2 diabetes and could prevent cancer in people without diabetes, research suggests.

Research by Dr Craig Currie of Cardiff University School of Medicine found metformin protects against cancer in people with type-2 diabetes, but insulin may increase cancer risk in a dose-dependent fashion.

He suggested that metformin could have a role in cancer prevention in people without diabetes.

People with type-2 diabetes on high insulin doses may benefit from screening and combination therapy with metformin.

Dr Jeffrey Johnson also presented data on cancer risk in people with type-2 diabetes. His research showed that the relationship between obesity, type-2 diabetes and cancer appears to be associated with insulin resistance and hyperinsulinemia.

He suggested glitazones may improve cancer outcomes.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

BMA demands meeting with Hancock over 'unrealistic demands' on GPs

BMA demands meeting with Hancock over 'unrealistic demands' on GPs

GP leaders at the BMA have demanded an urgent meeting with health and social care...

Join MIMS Learning Live June for four nights of clinical learning

Join MIMS Learning Live June for four nights of clinical learning

Across the MIMS Learning Live Digital series our expert speakers will bring you updates...

GP careers: The GP who helps defend doctors

GP careers: The GP who helps defend doctors

Dr John Dale-Skinner combines a salaried GP post with medico-legal work as a senior...

Map: Which CCGs have the highest COVID-19 vaccine coverage?

Map: Which CCGs have the highest COVID-19 vaccine coverage?

Tens of millions of COVID-19 jabs have been administered across England, but how...

GMC targets elimination of 'shameful' bias in regulation and education

GMC targets elimination of 'shameful' bias in regulation and education

The GMC has set a five-year target for eliminating disproportionate complaints from...

Viewpoint: False claims about GP access must be challenged - or practices really will close

Viewpoint: False claims about GP access must be challenged - or practices really will close

A high-profile public campaign is vital to counter damaging, false claims that GP...